Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA clears Carl Zeiss' OCT (Optical Coherence Tomographer) screener for retinal diseases:

This article was originally published in Clinica

Executive Summary

Carl Zeiss Ophthalmic Systems has received US FDA clearance to market its Optical Coherence Tomographer (OCT) model 3000 for screening for retinal diseases. The device provides real-time cross-sectional images of retinal tissue that have axial resolution of ten microns or less. It enables physicians to avoid invasive procedures and see below the surface of the retina, allowing them to directly measure internal retinal structures that can help in the diagnosis of diseases, such as glaucoma. A typical examination using the device takes less than 10 minutes, says the Dublin, California firm.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT065029

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel